Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ampio Pharmaceuticals has demonstrated the impact of low dose intranasal danazol on allergic rhinitis, following a randomized, placebo controlled, double-blinded proof of concept study.
Subscribe to our email newsletter
Danazol is a weak androgen approved at high doses for the treatment of endometriosis, fibrocystic disease of the breast and hereditary angioedema.
The study was intended to evaluate the effect of danazol in a clinical condition associated with vascular permeability and edema, which are the hallmark signs of allergic rhinitis.
During the course of the study, 20 patients were randomized to receive either intranasal danazol or placebo twice a day during a two week double-blind period which followed a one week washout period.
The data showed improvement in the intranasal danazol group but not in the placebo group.